A Quick Look at Today's Ratings for Viridian Therapeutics(VRDN.US), With a Forecast Between $22 to $50
This article provides a brief overview of recent analyst ratings for Viridian Therapeutics (VRDN.US), highlighting that analysts have set price targets ranging from $22 to $50. It indicates that the company's stock performance and future outlook are being assessed by financial experts.
VRDN: RBC Capital Lowers Price Target on Viridian Therapeutics | VRDN Stock News
RBC Capital has lowered its price target for Viridian Therapeutics (VRDN) to $30.00 from $42.00, while maintaining an "Outperform" rating. This adjustment is part of a broader trend among analysts, who have recently reduced price targets for VRDN despite mostly maintaining favorable ratings. Viridian Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for thyroid eye disease.
RBC Cuts Price Target on Viridian Therapeutics to $30 From $42, Keeps Outperform, Speculative Risk
RBC Capital Markets has lowered its price target for Viridian Therapeutics (VRDN) to $30 from $42, while maintaining an "Outperform" rating with a "Speculative Risk" designation. This adjustment comes despite RBC's view that Viridian's Thyroid Eye Disease (TED) franchise still represents a $1 billion opportunity. Another firm, Wedbush, also recently adjusted its price target for Viridian Therapeutics to $31 from $37, while similarly maintaining an "Outperform" rating.
Viridian Therapeutics (VRDN) slides 26.8% as investors digest Phase 3 REVEAL-1 data and reset expectations
Viridian Therapeutics (VRDN) shares dropped 26.8% after investors reacted negatively to the Phase 3 REVEAL-1 trial results for elegrobart, despite the study meeting its primary endpoint. Concerns about the drug's differentiation against existing treatments and subsequent analyst price target reductions have contributed to the market repricing. Attention now shifts to the REVEAL-2 trial expected in Q2 2026 and a Q1 2027 regulatory submission.
EBIT per share of Viridian Therapeutics, Inc. – LSE:0K1R
This article provides financial data specifically focusing on the EBIT per share for Viridian Therapeutics, Inc., traded on the London Stock Exchange under the ticker 0K1R. It presents a high-level overview of the company's financial performance metric.
A Look At Viridian Therapeutics (VRDN) Valuation After Positive REVEAL-1 Phase 3 Elegrobart Results
Viridian Therapeutics (VRDN) recently announced positive Phase 3 REVEAL-1 data for elegrobart, yet its share price momentum has faded despite these results. While the company appears expensive based on its Price-to-Sales (P/S) ratio of 27.2x compared to industry averages, Simply Wall St's Discounted Cash Flow (DCF) model suggests a significant intrinsic discount, estimating a future cash flow value of $160.81 per share against a current price of $18.84. This discrepancy highlights the market's current focus on the company's loss-making status and execution risks despite its high growth potential in treating rare diseases.
Viridian Therapeutics (VRDN) Is Down 32.5% After Debated Phase 3 Elegrobart Data - What's Changed
Viridian Therapeutics (VRDN) experienced a significant share price drop despite positive Phase 3 trial results for elegrobart, its active thyroid eye disease drug. The debate centers on how elegrobart differentiates itself from existing therapies, particularly due to its convenient subcutaneous dosing. The company's future hinges on upcoming veligrotug and REVEAL-2 readouts, with concerns arising about its valuation assumptions.
Viridian Therapeutics (VRDN) Target Price Lowered by Evercore IS
Evercore ISI Group's analyst, Maneka Mirchandaney, lowered the target price for Viridian Therapeutics (VRDN) from $45.00 to $32.00, while maintaining an "Outperform" rating. This adjustment reflects a 28.89% decrease and follows a trend of other analysts, including HC Wainwright & Co., Wells Fargo, Wedbush, Goldman Sachs, and Needham, also reducing their target prices for VRDN in late March 2026. Viridian Therapeutics is a clinical-stage biopharmaceutical company developing treatments for thyroid eye disease, with its main program focusing on veligrotug.
Viridian Therapeutics (VRDN) Is Down 32.5% After Debated Phase 3 Elegrobart Data - What's Changed
Viridian Therapeutics saw its shares drop 32.5% after reporting positive Phase 3 REVEAL-1 trial results for elegrobart, a drug for active thyroid eye disease. Despite positive outcomes, the market is debating how elegrobart will compete with existing therapies, focusing on its differentiation rather than outright success. Future catalysts for Viridian include the veligrotug PDUFA decision and REVEAL-2 readout, but commercial positioning and valuation concerns now weigh on the investment narrative.
Viridian Therapeutics (VRDN) Soars 5.6%: Is Further Upside Left in the Stock?
Viridian Therapeutics (VRDN) shares recently surged 5.6% following positive top-line data from its phase III REVEAL-1 study for active thyroid eye disease, with elegrobart meeting its primary endpoint. Despite this rally, the article notes that earnings estimate revisions have remained unchanged, suggesting that continued upward momentum might be limited without further positive trends in estimates. The stock currently holds a Zacks Rank #3 (Hold), indicating that while the recent news is positive, its future performance will depend on continued favorable developments.
Viridian Therapeutics (VRDN) Jumps 5.6%: Does the Stock Have More Room to Grow?
Viridian Therapeutics (VRDN) saw its stock jump 5.6% after reporting positive top-line results from its phase III REVEAL-1 trial for elegrobart in thyroid eye disease. The study met its primary endpoint with strong proptosis responder rates compared to placebo, leading to high trading volume. Despite this rally, the company faces projected quarterly losses and revenue increases, with its Zacks Rank currently at #3 (Hold), suggesting a need to monitor earnings estimate revisions for sustained momentum.
Viridian releases phase 3 topline data on elegrobart for TED
Viridian Therapeutics announced positive topline data from its REVEAL-1 phase 3 trial for elegrobart, an anti-IGF-1R monoclonal antibody for thyroid eye disease (TED). The study met its primary and key secondary endpoints with high statistical significance, showing improvement in proptosis and diplopia responder rates for both Q4W and Q8W dosing. Viridian expects to submit a Biologics License Application (BLA) for elegrobart by early 2027, potentially making it the first subcutaneous autoinjector treatment for TED.
Viridian Therapeutics (NASDAQ:VRDN) Given New $37.00 Price Target at Wedbush
Wedbush has lowered its price target for Viridian Therapeutics (NASDAQ:VRDN) to $37.00 from $44.00, while maintaining an "outperform" rating, suggesting a significant upside. This adjustment comes despite the company's Phase 3 REVEAL‑1 trial for elegrobart meeting its primary endpoint, as the stock experienced a sharp intraday drop and an earnings per share miss. Viridian Therapeutics continues to hold a "Moderate Buy" consensus rating among analysts with an average target of $39.50.
Viridian Therapeutics, Inc. Shareholders Are Encouraged to
Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Viridian Therapeutics, Inc. (NASDAQ: VRDN). The investigation focuses on whether Viridian's executive officers complied with federal securities laws following the announcement of topline results from its REVEAL-1 Phase 3 clinical trial. Shareholders who suffered losses are encouraged to contact Johnson Fistel for more information.
Viridian Therapeutics (VRDN) Analyst Ratings Update: Wells Fargo Lowers Price Target | VRDN Stock News
Wells Fargo has reaffirmed its "Equal-Weight" rating for Viridian Therapeutics (VRDN) but has lowered its price target by 31.03% from $29.00 to $20.00. This adjustment comes amidst other analyst updates, with the average one-year price target from 17 analysts being $37.82, suggesting a potential upside of 102.92% from the current price. Viridian Therapeutics is focused on developing product candidates for thyroid eye disease, including veligrotug and elegrobart.
Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑1 Clinical Trial in Active Thyroid Eye Disease
Viridian Therapeutics announced positive topline results from its elegrobart Phase 3 REVEAL-1 clinical trial for active Thyroid Eye Disease (TED). The study met its primary endpoint, showing a highly statistically significant proptosis responder rate, and elegrobart was generally well-tolerated. These results position elegrobart as a potential first-ever subcutaneous autoinjector treatment for TED, with a Biologics License Application (BLA) submission anticipated in Q1 2027.
Viridian plunges on topline late-stage results for elegrobart for thyroid eye disease (VRDN:NASDAQ)
Viridian Therapeutics (VRDN) experienced a significant stock drop of approximately 32% following the release of topline results from a Phase 3 trial for its thyroid eye disease drug, elegrobart. Despite the company labeling the results as positive and meeting the primary endpoint, investors reacted negatively to the announcement.
Viridian Therapeutics (NASDAQ:VRDN) Shares Gap Down - What's Next?
Viridian Therapeutics (NASDAQ:VRDN) shares gapped down by approximately 33.4% following a disappointing quarterly report, missing both EPS and revenue estimates. Despite the significant drop, analysts maintain a "Moderate Buy" consensus with an average price target of $42.21, although the company remains unprofitable. Insider selling was reported, and institutional investors showed mixed activity in recent quarters.
Viridian Therapeutics shares fall over 30% after trial data disappoints
Viridian Therapeutics shares dropped over 30% after its REVEAL-1 trial for elegrobart in thyroid eye disease (TED) showed efficacy below investor expectations, despite meeting its primary endpoint. While the subcutaneous formulation could expand the TED market, particularly for infusion-averse patients, its commercial potential is debated due to weaker efficacy compared to intravenous competitors. Jefferies maintained a Buy rating, suggesting elegrobart could complement existing therapies and capture a significant portion of the chronic TED market.
Viridian Therapeutics’ stock sinks despite positive Phase III TED data
Viridian Therapeutics' stock plummeted by 38% despite its thyroid eye disease (TED) drug, elegrobart, meeting primary endpoints in a Phase III trial. Investors' confidence may have been shaken by the proptosis responder rates being lower than anticipated, raising concerns about elegrobart's competitiveness against existing marketed therapies like Amgen's Tepezza. Viridian also awaits an FDA decision on veligrotug, with a PDUFA target action date of June 30, 2026.
Viridian sinks as eye disease drug disappoints on efficacy despite trial success
Viridian Therapeutics' shares dropped significantly after its experimental thyroid eye disease drug, elegrobart, showed disappointing efficacy in a late-stage study, despite meeting its primary goal of reducing eye bulging. Analysts noted that the improvements were less than investor expectations and lagged behind rival treatments. The company plans to submit a U.S. marketing application in early 2027, hoping a home-administered therapy could expand the market.
Viridian Therapeutics crashes on 'positive, but lackluster' thyroid eye disease results
Viridian Therapeutics' stock plummeted following the release of Phase 3 trial results for its thyroid eye disease treatments, VRDN-001 and VRDN-002. While the results were positive, analysts deemed them "lackluster," especially when compared to Tepezza, a currently approved treatment, leading to investor disappointment and a significant drop in share value. The market reacted negatively due to the therapies showing no clear advantage over existing options.
Why Is Viridian Therapeutics Stock Falling Monday?
Viridian Therapeutics (NASDAQ:VRDN) stock fell in premarket trading after announcing topline results from its REVEAL-1 Phase 3 clinical trial for elegrobart, a treatment for thyroid eye disease (TED). While the trial met its primary endpoint, the placebo-adjusted proptosis responder rates were lower than investors expected, leading to concerns about its commercial viability compared to competitors. Despite this, the company's strong cash position and pipeline suggest long-term strategy support.
Viridian Therapeutics (VRDN) reports positive phase 3 elegrobart results and details TED pipeline
Viridian Therapeutics announced positive topline results from its REVEAL-1 Phase 3 clinical trial of elegrobart in active Thyroid Eye Disease (TED), meeting the primary endpoint with high statistical significance. The company reported robust proptosis and diplopia responses with a generally well-tolerated safety profile for both Q4W and Q8W dosing arms. Viridian is also progressing veligrotug towards a PDUFA action date of June 30, 2026, and anticipates submitting a BLA for elegrobart in Q1 2027, with existing cash expected to fund operations through profitability.
Viridian Therapeutics stock tumbles despite trial success
Viridian Therapeutics (NASDAQ:VRDN) shares dropped 40% despite its elegrobart Phase 3 REVEAL-1 clinical trial successfully meeting its primary endpoint for active thyroid eye disease. The drug showed highly statistically significant treatment effects in proptosis responder rates compared to placebo. The company plans to submit a Biologics License Application to the FDA in Q1 2027 and has another candidate, veligrotug, under Priority Review.
Viridian's thyroid eye disease shot beat placebo in Phase 3 trial
Viridian Therapeutics announced positive topline results from its elegrobart REVEAL-1 Phase 3 clinical trial for active thyroid eye disease (TED), meeting its primary endpoint with high statistical significance. The subcutaneously administered drug demonstrated clinically meaningful reductions in proptosis and diplopia compared to placebo, with a generally well-tolerated safety profile. The company expects a Biologics License Application (BLA) submission for elegrobart in Q1 2027 and is preparing for the potential launch of veligrotug, another TED treatment, with a PDUFA target action date of June 30, 2026.
Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑1 Clinical Trial in Active Thyroid Eye Disease
Viridian Therapeutics announced positive topline results from its elegrobart Phase 3 REVEAL-1 clinical trial for active Thyroid Eye Disease (TED), meeting the primary endpoint for proptosis responder rate with high statistical significance. Elegrobart, a subcutaneously delivered antibody, showed clinically meaningful proptosis and diplopia responses, and was generally well-tolerated. The company anticipates a Biologics License Application (BLA) submission in Q1 2027, highlighting its potential as a convenient, self-administered treatment option for TED.
Vanguard (VRDN) amendment shows 0 shares; subsidiaries to report separately
The Vanguard Group filed an amended Schedule 13G/A report indicating 0 beneficial shares of Viridian Therapeutics Inc. (VRDN) common stock, representing 0% ownership. This change is due to an internal realignment within Vanguard, where certain subsidiaries will now report their holdings separately, as per SEC Release No. 34-39538. The filing clarifies that this amendment reflects a reporting structure change rather than a sale or purchase of shares, with subsequent filings by Vanguard affiliates expected to show their individual holdings.
Fund Sells $81M in Viridian Stock: Q4 2025 Portfolio Shift - News and Statistics
Kynam Capital Management significantly reduced its stake in Viridian Therapeutics during Q4 2025, selling 2,957,386 shares valued at approximately $81.11 million. This transaction reflects a portfolio shift, decreasing their remaining investment in Viridian by $49.79 million. Viridian Therapeutics, a clinical-stage biotechnology company focused on thyroid eye disease, currently has a market valuation of $2.8 billion and reported trailing twelve-month revenues of $70.79 million.
Kynam Capital Management Cuts Viridian Stake by Over $81 Million
Kynam Capital Management sold 2,957,386 shares of Viridian Therapeutics in Q4 2026, reducing its stake by over $81 million and signaling a cautious outlook, despite the stock's 76% surge over the past year. Viridian (VRDN) faces substantial R&D costs and net losses but holds significant cash reserves for future clinical trials. Analyst ratings largely recommend "Buy," with a consensus forecast for price appreciation, though RBC Capital recently lowered its price target.
Hudson Bay Capital Management LP Raises Stake in Viridian Therapeutics, Inc. $VRDN
Hudson Bay Capital Management LP increased its stake in Viridian Therapeutics (NASDAQ:VRDN) by 46.6% in the third quarter, now owning 175,251 shares valued at $3.78 million, with other institutional investors also boosting their positions. Despite the company missing quarterly earnings and revenue expectations significantly, analysts largely maintain a "Moderate Buy" rating with an average price target of $42.21. Viridian Therapeutics continues to focus on developing targeted antibody therapeutics for rare and serious diseases.
This fund recently reduced its holding in a Viridian stock by more than $80 million. What does this mean for investors?
Kynam Capital Management reduced its stake in Viridian Therapeutics (NASDAQ:VRDN) by over $80 million, selling nearly 3 million shares in the fourth quarter. This move is interpreted as a portfolio rebalancing strategy rather than a lack of confidence, given Viridian's significant rally and its subsequent presence as 2.92% of Kynam's assets under management. Investors are advised to consider upcoming clinical data and the company's strong cash position, while noting that Viridian did not make The Motley Fool Stock Advisor's list of top 10 stocks.
Is It Time To Reassess Viridian Therapeutics (VRDN) After Its Strong 1-Year Share Price Run?
Viridian Therapeutics (VRDN) has seen a significant 76.8% gain over the past year, despite recent short-term declines. A Discounted Cash Flow (DCF) analysis suggests the stock is significantly undervalued, estimating an intrinsic value of $168.28 compared to its current price of approximately $26.98. However, its Price-to-Sales (P/S) ratio of 38.92x, much higher than the biotech industry average, indicates it is overvalued based on sales multiples.
VRDN SEC Filings - Viridian Therapeutics Inc 10-K, 10-Q, 8-K Forms
This page provides comprehensive access to Viridian Therapeutics (VRDN) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K material event filings, and insider trading forms. It details the company's focus on biopharmaceutical development for serious and rare diseases, its financial activities, and crucial events like public offerings and collaboration agreements. Stock Titan enhances this information with AI-powered summaries of these regulatory disclosures.
Commodore Capital LP Cuts Stake in Viridian Therapeutics, Inc. $VRDN
Commodore Capital LP significantly reduced its stake in Viridian Therapeutics (NASDAQ:VRDN) by 34.4% in the third quarter, selling 1.675 million shares but still holding 3.2 million shares valued at approximately $69.06 million, making it 3.4% of their portfolio. This move follows a disappointing quarter for Viridian, which missed EPS and revenue expectations. Despite the poor financial results and share reduction by Commodore Capital, analysts maintain a "Moderate Buy" consensus rating with an average target price of $42.21, although some have adjusted their price targets.
VRDN: Wedbush Reiterates 'Outperform' Rating with $44 Target | V
Wedbush has reiterated its 'Outperform' rating for Viridian Therapeutics (VRDN), maintaining a price target of $44.00, signaling continued confidence in the company's stock. This update comes amidst several other analyst ratings in recent months, with varying price targets but a general consensus leaning towards "Outperform" for the clinical-stage biopharmaceutical company. Viridian Therapeutics focuses on developing treatments for thyroid eye disease, with an average target price from analysts suggesting a significant upside from its current trading price.
Viridian Therapeutics, Kissei Pharmaceutical Partner for Japanese Development of Thyroid Eye Disease Therapies, Securing $70M Upfront
Viridian Therapeutics has partnered with Kissei Pharmaceutical for the development and commercialization of VRDN-001 and VRDN-003, their antibody therapies for Thyroid Eye Disease (TED), in Japan. This collaboration grants Kissei exclusive rights to both compounds in the region. Viridian receives a $70 million upfront payment and is eligible for additional development, regulatory, and sales-based milestone payments, as well as royalties on net sales.
RBC Capital lowers its price target on Viridian Therapeutics, Inc. (VRDN) to $42 and maintains an outperform rating
RBC Capital has lowered its price target for Viridian Therapeutics, Inc. (VRDN) to $42, while reiterating an "outperform" rating on the stock. This adjustment reflects a revised valuation perspective despite maintaining a positive outlook on the company's performance.
Wedbush Reaffirms Outperform Rating for Viridian Therapeutics (NASDAQ:VRDN)
Wedbush has reiterated an "Outperform" rating for Viridian Therapeutics (NASDAQ:VRDN), setting a $44 price target that suggests a 50.7% upside. Despite the company missing earnings and revenue estimates in its last quarterly report, several major institutional investors increased their holdings. Analyst consensus for VRDN is a "Moderate Buy," with an average price target of $42.21.
(VRDN) Movement Within Algorithmic Entry Frameworks
This article analyzes Viridian Therapeutics Inc. (NASDAQ: VRDN) using algorithmic entry frameworks. It indicates a near-term neutral sentiment but mid and long-term strength, with support being tested. The analysis presents three trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis and a strong risk-reward setup.
Viridian Therapeutics (NASDAQ: VRDN) CEO amends Form 4 tax sale
Viridian Therapeutics CEO Stephen F. Mahoney amended a Form 4 filing to correct details regarding a sale of 7,408 common shares on March 3, 2026, at $30.19 each. This sale was conducted to cover tax obligations, not as an open-market transaction. The corrected filing indicates that Mahoney now beneficially owns 33,349 shares of Viridian Therapeutics.
Viridian Therapeutics (VRDN) legal chief updates tax share disposition
Viridian Therapeutics' Chief Legal Officer, Jennifer Tousignant, filed an amended Form 4 to correct details of a tax-related share disposition. The amendment clarifies that 1,675 shares of common stock were disposed of at $30.19 per share on March 3, 2026, to cover taxes, leaving her with 3,494 directly held shares. This filing aims to rectify previous reporting errors regarding the number of shares and price.
Does Viridian’s Veligrotug FDA Path And New Shelf Offering Reframe The Bull Case For VRDN?
In February 2026, Viridian Therapeutics (VRDN) reported its Q4 and full-year 2025 financial results, showing modest revenue but increased net losses. The company also filed a US$16.33 million stock shelf registration. Investor focus remains on the potential FDA approval of veligrotug for thyroid eye disease, with a PDUFA date of June 30 and commercial launch preparations for mid-2026, alongside upcoming clinical data for elegrobart.
Viridian Therapeutics (NASDAQ:VRDN) Downgraded to "Sell" Rating by Wall Street Zen
Wall Street Zen has downgraded Viridian Therapeutics (NASDAQ:VRDN) from a "hold" to a "sell" rating, despite a broader "Moderate Buy" consensus among 13 other analysts. The downgrade follows the company reporting earnings per share of ($1.08) against an expected ($0.90) and significantly missed revenue forecasts. However, institutional investors like Perceptive Advisors, Morgan Stanley, and Vanguard Group have increased their holdings, indicating continued interest despite the negative earnings and downgrade.
Form 4 Viridian Therapeutics Inc For: 5 March
This article announces the filing of Form 4 for Viridian Therapeutics Inc. on March 5th. It is a brief administrative notice indicating an insider transaction or change in ownership for the company. The article provides minimal details beyond the filing date and company name.
RBC Capital Lowers Its Price Target on Viridian Therapeutics, Inc. (VRDN) to $42 and Maintains an Outperform Rating
RBC Capital has lowered its price target for Viridian Therapeutics (VRDN) to $42 from $45, while maintaining an Outperform rating. This adjustment follows the company's Q4 earnings report and the confirmation of a June 30 PDUFA date for veligrotug, with a potential commercial launch in mid-2026. Separately, Jefferies raised its price target to $45, emphasizing that key events, including Phase 3 data for elegrobart and the PDUFA decision for veligrotug, remain on track.
Vanguard Group Inc. Has $93.48 Million Holdings in Viridian Therapeutics, Inc. $VRDN
Vanguard Group Inc. reduced its stake in Viridian Therapeutics (NASDAQ:VRDN) by 3.9% in the third quarter, now holding 5.30% of the company worth approximately $93.48 million. This comes after Viridian reported a disappointing quarter, missing EPS and revenue estimates significantly. Despite the poor financial performance, analysts largely maintain a "Moderate Buy" rating with an average price target of $42.43.
RBC Capital Lowers Its Price Target on Viridian Therapeutics, Inc. (VRDN) to $42 and Maintains an Outperform Rating
RBC Capital has lowered its price target for Viridian Therapeutics (VRDN) to $42 from $45, while maintaining an Outperform rating. This change follows the company's Q4 earnings report and the announcement of a PDUFA date of June 30 for veligrotug, with preparations for a potential commercial launch in mid-2026. Jefferies also recently raised its price target for VRDN, citing all key events remaining on track, including upcoming Phase 3 trial readouts for elegrobart.
Propel Bio Management LLC Makes New Investment in Viridian Therapeutics, Inc. $VRDN
Propel Bio Management LLC recently acquired 90,000 shares of Viridian Therapeutics (NASDAQ:VRDN) worth approximately $1.94 million, making it 1.9% of Propel's holdings. Despite this, Viridian Therapeutics last reported substantial earnings misses, with EPS of -$1.08 against an expected -$0.90 and revenue of $0.13 million compared to an expected $15.75 million. Analysts, however, maintain a "Moderate Buy" rating with an average target price of $42.43.
[144] Viridian Therapeutics, Inc.DE SEC Filing
This article reports on a Form 144 SEC filing by Viridian Therapeutics, Inc. (VRDN), dated March 4, 2026. The filing indicates a neutrality in impact and sentiment, detailing the proposed sale of securities via restricted stock vesting. It outlines the filer and issuer information, securities to be sold, and confirms no securities were sold in the past three months.
